Biotop-report 2012

39

BioTOPics 44 | May 2012 

BioTOP-Report

Epigenomics AG

Epigenomics is a molecular diagnostics com-

pany developing and commercializing a 

pipeline of proprietary products for cancer. 

The Company’s products enable doctors to 

diagnose cancer earlier and more accurately, 

leading to improved outcomes for patients. 

Epigenomics’ lead product, Epi proColon

®

 

2.0, is a second generation blood-based test 

for the early detection of colorectal cancer, 

which is currently marketed in Europe and is 

in development for the U.S.A. 

With clinical studies indicating a majority of 

colorectal cancers are detected with the test 

added to the convenience of a simple blood 

draw, Epi proColon

®

 is expected to improve 

compliance for colorectal cancer screening 

and save lives through early detection of dis-

ease. Laboratory test services based on this 

technology are available in the U.S.A. and 

Canada by our partnering laboratories Quest, 

ARUP and Warnex. 

Epigenomics’ product portfolio further 

includes Epi proLung

®

, a confirmatory test 

aiding in the diagnosis of lung cancer that is 

marketed in Europe, and additional products 

in development for colorectal, lung and 

prostate cancer. The Company’s technology 

and products have been validated through 

multiple partnerships with leading global 

diagnostic companies including Abbott, QIA-

GEN, Sysmex, and Quest Diagnostics. Epig-

enomics is an international company with 

operations in Berlin, Germany, and Seattle, 

WA, U.S.A. 

For further information please visit 

www.epigenomics.com

Address 

Epigenomics AG

Kleine Praesidentenstraße 1

10178 Berlin · Germany

Phone [phone]

Fax 

[phone]

[e-mail]

www.epigenomics.com

BioTeZ Berlin-Buch GmbH

BioTeZ is focused on biotechnological prod-

ucts and services for life science research, 

pharmaceutical industry and diagnostics.

 

In many business fields BioTeZ has own tech-

nologies with outstanding properties, e.g., in 

the sphere of immunoaffinity columns, HRP-

labeling, sundry streptavidin coatings and 

the development of enzyme immunoassays. 

On the basis of many years' experience the 

powerful diagnostic tool recoveryELISA

®

 was 

created for monitoring therapies with bio-

logics. 

Business fields at a glance:

Immunoaffinity chromatography

 

k

Production of customized IAC

 

k

Coupling of different ligands, 

e.g. antibodies against mycotoxins

Premium oligonucleotid synthesis

 

k

DNA / RNA  incl.  modifications

Streptavidin coating

 

k

Microplates and other surfaces and 

materials

 

k

Polystrept R for high binding capacity, 

excellent for lateral flow assays

ELISA development and services

 

k

inclusive conjugate development, 

labeling, purification etc.

Companion Diagnostics

 

k

recoveryELISA

®

 – a  new  diagnostic 

method to predict and to measure inter-

action between therapeutic antibodies or 

biologics and their target molecules. 

Contact

BioTeZ Berlin-Buch GmbH

Robert-Rössle-Straße 10

13125 Berlin · Germany

Phone [phone]

Fax 

[phone]

[e-mail]

www.biotez.de

---

40

BioTOPics 44 | May 2012 

BioTOP-Report

Metanomics Health GmbH 

Metanomics Health – a BASF Group compa-

ny – applies comprehensive Metabolite Pro-

filing (metabolomics) with biomedical data 

interpretation. Metabolite Profiling is 

defined as the parallel analysis of multiple 

endogenous and xenobiotic metabolites in 

biological systems. The core expertise of 

Metanomics Health resides in discovery and 

validation of biomarkers.

Technologies

 

k

Metabolite profiling platform with more 

than 75 GC-MS and LC-MS/MS instru-

ments

 

k

Wide metabolite coverage via combina-

tion of unbiased and targeted platforms

 

k

Unique tox mode of action prediction 

through MetaMap

®

Tox database

 

k

Excellence in systems correlation analy-

sis of complex gene function relation-

ships

Major R&D-Topics

In cooperation with academic institutes and 

clinical experts Metanomics Health is run-

ning a large-scale diagnostic biomarker pro-

gram. Areas include metabolic syndrome, 

heart failure, prostate cancer and multiple 

sclerosis to mention a few.

Market Segments

Metanomics Health provides its services to 

pharmaceutical, diagnostics and nutrition 

companies. Technology applications include:

 

k

Mechanism of action studies

 

k

Mechanism of toxicity studies

 

k

Translational and clinical biomarker 

development (e.g. PK/PD, patient stratifi-

cation, efficacy and safety markers)

 

k

Companion diagnostic development

 

k

Cell culture & bioprocess optimization

Address

Metanomics Health GmbH 

Tegeler Weg 33

10589 Berlin · Germany

Contact

Dr. Tim Bölke · Managing Director

Phone [phone]

Fax 

[phone]

[e-mail]

www.metanomics-health.de

Alacris Theranostics GmbH 

Alacris Theranostics GmbH, operative since 

September 2011, is specialised in develop-

ing new approaches in personalised medi-

cine for cancer patient diagnosis, treatment 

and drug stratification. Alacris has built up a 

next-generation sequencing center for the 

analysis of clinical samples and applies a sys-

tems biology approach for patient and drug 

stratification using the ModCell

TM

 software 

which is exclusively licensed to Alacris. This 

approach has been originally developed in 

the department of Prof. Lehrach at the Max 

Planck Institute for Molecular Genetics. 

Based on genome and transcriptome infor-

mation and including kinetic pathway infor-

mation, mutation and drug databases it is 

providing a “Virtual Patient” model. This 

”Virtual Patient” can predict the effects of 

chemotherapeutic treatment and optimised 

combinatory treatment for personalised 

medicine approaches. ModCell

TM

 also facili-

tates biomarker discovery and "Virtual Clini-

cal Trials" for patient and drug stratification. 

Alacris' work provides the opportunity for:

 

k

finding targeted personalised treatment 

for the patient 

 

k

saving negative side effects 

 

k

reducing health costs for non-necessary 

treatment 

 

k

optimising stratification of drug treat-

ment 

 

k

providing more rapid approval of drugs 

in targeted non-randomised trials 

 

k

recovering "fallen angel" drugs for the 

pharmaceutical industry 

 

k

reducing animal testing via virtual trials 

Address 

Alacris Theranostics GmbH

Fabeckstraße 60-62

14195 Berlin · Germany

[e-mail]

www.alacris.de

Unlocking The Power Of

Individualised Medicine

---